Ziopharm Oncology, Inc. (NASDAQ: ZIOP), is collaborating with Aldevron to secure rapid neoGMP® plasmid DNA manufacturing for Ziopharm's Sleeping Beauty construct to express TCRs for treatment of solid tumors. 

Attracting one of med-tech’s most accomplished executives, Aldevron has named Kevin Ballinger as Chief Executive Officer, effective July 13, 2020. Aldevron’s co-founder, Michael Chambers, has been named Executive Chairman of the board. Chambers initiated the transition to allow him to focus on innovation, corporate strategy and working with clients and industry thought leaders to develop new technologies that enable genetic medicine. Ballinger will assume day-to-day operational leadership of Aldevron, facilitating the company’s rapid growth.

Genprex, Inc. (NASDAQ: GNPX), is collaborating with Aldevron to secure GMP plasmid DNA manufacturing capacity for Genprex's Oncoprex™ gene therapy portfolio.

The manufacturing program supports upcoming clinical trials, including Oncoprex™ in combination with Tagrisso®, which has received FDA Fast Track Designation. The collaboration with Aldevron will enable full commercial scale plasmid DNA manufacturing capabilities.